The estimated Net Worth of Leon O Jr Moulder is at least $749 Tisíc dollars as of 1 February 2019. Mr. Moulder owns over 100,000 units of Trevena Inc stock worth over $749,000 and over the last 11 years he sold TRVN stock worth over $0. In addition, he makes $0 as Independent Chairman of the Board at Trevena Inc.
Leon has made over 5 trades of the Trevena Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of TRVN stock worth $102,000 on 1 February 2019.
The largest trade he's ever made was buying 100,000 units of Trevena Inc stock on 1 February 2019 worth over $102,000. On average, Leon trades about 9,167 units every 76 days since 2014. As of 1 February 2019 he still owns at least 100,000 units of Trevena Inc stock.
You can see the complete history of Mr. Moulder stock trades at the bottom of the page.
Leon (Lonnie) O. Moulder Jr. serves as Independent Chairman of the Board of the Company. Mr. Moulder has served as Chairman of the Board since June 2013. Mr. Moulder is General Partner of Tellus BioVentures, LLC, a life science investment fund he founded in March 2019. From May 2010 to January 2019, Mr. Moulder was the co-founder, Chief Executive Officer and a member of the board of directors of TESARO, Inc. (TSRO), a public oncology-focused biopharmaceutical company that was acquired by GlaxoSmithKline plc. From April 2009 to January 2010, Mr. Moulder served as Vice Chairman of the board of directors, President and Chief Executive Officer of Abraxis BioScience, Inc., a biotechnology company. Before that, Mr. Moulder served as Vice Chairman of Eisai Corporation of North America, a pharmaceutical company and wholly owned subsidiary of Eisai Co., Ltd. (OTCMKTS: ESALF), from January 2008 until January 2009, following Eisai Co., Ltd.’s acquisition of MGI PHARMA, Inc., in January 2008. Mr. Moulder served as President and Chief Executive Officer and as a member of the board of directors of MGI PHARMA, Inc. from May 2003 to January 2008. In January 2020, Mr. Moulder joined the board of directors of Zai Lab Ltd. (ZLAB), a biopharmaceutical company. Mr. Moulder earned a B.S. in pharmacy from Temple University and a M.B.A. from the University of Chicago. Mr. Moulder is a Trustee of Temple University, serves as a board member for several privately held biotechnology companies and previously served as a director of Cubist Pharmaceuticals, Inc. from February 2010 until January 2015.
Leon Moulder is 62, he's been the Independent Chairman of the Board of Trevena Inc since 2013. There are 3 older and 10 younger executives at Trevena Inc. The oldest executive at Trevena Inc is Anne Phillips, 66, who is the Independent Director.
Leon's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142.
Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire a Partners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.
trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
Trevena Inc executives and other stock owners filed with the SEC include: